Contact LinkedIn Twitter

Martin Nicklasson

Chairman of the Board – Chairman of the Remuneration and Compensation Committee and Chairman of the Nomination Committee

Dr. Martin Nicklasson, (1955) was elected as Chairman of the Board of Directors of Zealand in 2015.
Martin has held various Executive Vice President positions at AstraZeneca Plc and has served as President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB. Prior to this he held a number of leadership positions at Astra and Kabi Pharmacia. Martin Nicklasson is chairman of the board of Orexo AB, Farma Holding and Basilea Pharmaceutica Ltd. He serves as a board member in Biocrine AB, PledPharma AB and Premier Research Group Ltd., and is also on the board of the Swedish Heart and Lung foundation. Martin is a certified pharmacist and holds a PhD in Pharmaceutical Technology from the Uppsala University, where he is Associate Professor at the Department of Pharmaceutics.

Rosemary Crane

Vice Chairman of the Board

Rosemary Crane (1960) was elected to the Board of Directors of Zealand in 2015, and is an independent member.
Rosemary Crane has been CEO of Mela Science (2013-2014) and Epocrates (2008-2011), besides having held a number of leading positions in Johnson & Johnson and BMS. Rose has a background in marketing and has a knowledge base in diabetes and cardiovascular diseases among others.

Rosemary Crane is a member of the Advisory Board of Oswego State University Business School, The Foundation Board of Oswego State University and the Transplant House Committee at University of Pennsylvania.

Alain Munoz

Independent Board member – Chairman of the Clinical and Scientific Advisory Board

Alain Munoz (1949) has been member of the Board since 2005 (resigned in 2006, and re-elected in 2007), and is an independent member.
Alain Munoz is CEO and founder of Amistad Pharma S.A.S. (France) and Science, Business and Management SARL (France), and has over 20 years of experience in the pharmaceutical industry at senior management level. Within the Sanofi Group he served as SVP for International development (France) and in Fournier Laboratories as SVP for the Pharmaceutical division (France). He is a member of the Board of Valneva (France), Auris medical AG (Switzerland), Medesis Pharma SA (France) and Hybrigenics SA (France).
Alain Munoz holds an MD in Cardiology and Anaesthesiology from the Hospital Pitié-Salpétrière, Paris. He has numerous publications and has been a member of the scientific committee of the French Drug Agency.

Michael J. Owen

Independent board member

Michael J. Owen (1951) was elected to the Board of Zealand in 2012, and is regarded as an independent board member.

Michael J. Owen is a co-founder and was CSO at Kymab Ltd. (UK). Before joining Kymab, he had several leading positions at GlaxoSmithKline, latterly as SVP and head of biopharmaceuticals research. Prior to joining GSK in 2001, he headed the Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He has more than 20 years of research experience with a focus on the immune system. He has more than 150 publications and membership of the European Molecular Biology Organisation and Fellowship of the Academy of Medical Sciences. He is a member of the Board of Ossianix, Inc. (USA) and BLINK Therapeutics (UK).
Michael J. Owen holds a PhD in amino acid transport in trypanosomes from Cambridge University, and a BA in Biochemistry from Keble College, Oxford University.

Catherine Moukheibir

Board member – Chairman of the Audit Committee

Catherine Moukheibir was elected to the Board of Directors of Zealand in 2015.
Catherine Moukheibir has held senior management positions in several European biotech companies after an initial career in strategy consulting and investment banking in Boston and London. Her particular experience lies in aligning corporate and financial strategy at various stages of a biotech’s development, and she is currently a non-executive Board member of Creabilis and Ablynx and a member of the management board at Innate Pharma. Catherine Moukheibir holds an MBA from Yale University.

Peter Benson

Independent board member

Peter Benson (1955) has been member of the Board since 2007, and served as Vice Chairman 2010-2011. He is regarded as an independent board member.
Peter Benson is Managing Partner of Sunstone Capital and earlier was Partner and Head of Life Science Ventures from 2003. Prior to founding Sunstone Capital, he spent 20 years in the life science industry, including as President of Pharmacia and Manager for the division Hospital Care.
Peter also served on a number of Life Science boards, including the currently public listed companies Biogaia (Sweden), Ortivus (Sweden), Cellavision AB (Sweden) and Optovent AB (Sweden). Mr. Benson serves as a member of the Board of Asante Solutions Inc. (USA), Arcoma AB (Sweden), Alligator bioscience AB (Sweden) and Opsona Therapeutics Ltd (Ireland).
Peter Benson holds a Bachelor of Business Administration from the University of Lund and a M.A. in Economics from the University of California.

Christian Thorkildsen

Board member/employee elected

Christian Thorkildsen (1968) has been member of the Board since 2005. Christian Thorkildsen is Project Director at Zealand. Mr. Thorkildsen holds an M.Sc. (Pharm) from the Danish University of Pharmaceutical Sciences.

Helle Størum

Board member/employee elected

Helle Størum (1967) has been member of the Board since 2008. Helle Størum is Director and Head of Business Development at Zealand.
Helle Størum has more than 17 years of experience in the pharmaceutical industry, working with business development, market research, competitive Intelligence, forecasting and financial evaluations. She has previously been employed at Nycomed A/S and H. Lundbeck A/S. Helle Størum holds a M.Sc. (Economics) from University of Southern Denmark and a Diploma in Basic Pharmaceutical Medicine.

Jens Peter Stenvang

Board member/employee elected

Jens Peter Stenvang (1954) has been member of the Board since 2014. Jens Peter holds a degree as laboratory technician in biology and has worked with cancer and diabetes research at leading universities including UC-Berkeley, California. Before joining Zealand in October 2010, Jens Peter worked for DAKO and Beckman Coulter as global Flow Cytometry support. Jens Peter has been member of the board of Dansk Selskab for Flowcytometri since 1990, excluding a short break from 2010-2012.